Oppenheimer Raises Gilead Sciences (GILD) Price Target to $115

Author's Avatar
Dec 11, 2024
Article's Main Image

Oppenheimer has increased the price target for Gilead Sciences (GILD, Financial) from $105 to $115. The firm maintains its "Outperform" rating, indicating confidence in Gilead's potential to exceed market expectations.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.